Vitamin B12 / Folate

Vitamin B12 (cobalamin) and folate (vitamin B9) are water-soluble vitamins that function as obligate cofactors in one-carbon metabolism, the central metabolic hub that transfers single-carbon units between biochemical reactions. Vitamin B12 exists in multiple forms: cyanocobalamin (the most stable synthetic form), hydroxocobalamin (the predominant form in human plasma), methylcobalamin (the active form in the cytosol and the cofactor for methionine synthase), and adenosylcobalamin (the active form in mitochondria and the cofactor for methylmalonyl-CoA mutase). Folate encompasses a family of compounds based on tetrahydrofolate (THF), including dietary polyglutamated folates from leafy green vegetables, synthetic folic acid used in fortification and supplements, and the active circulating form 5-methyltetrahydrofolate (5-MTHF). Dietary folates are approximately 50% bioavailable compared to folic acid, and MTHFR enzyme activity (which converts dihydrofolate to 5-MTHF) is the rate-limiting step in activating supplemental folic acid. The MTHFR C677T polymorphism, present in homozygous form in 10-15% of Northern European populations and higher frequencies in some Mediterranean and Asian populations, reduces MTHFR enzyme activity by 60-70% and has profound implications for folate-dependent processes.

The biochemical unity between B12 and folate centers on the methionine synthase reaction, the metabolic step at which the pathways converge. Methionine synthase (encoded by MTR) catalyzes the transfer of a methyl group from 5-methyltetrahydrofolate to homocysteine, requiring methylcobalamin as an obligate cofactor. This reaction accomplishes two simultaneous outcomes: it regenerates methionine from homocysteine (lowering plasma homocysteine) and it regenerates tetrahydrofolate from the methylated folate (permitting re-entry into the folate cycle for thymidylate synthesis and purine biosynthesis). Methionine produced by this reaction is then adenosylated to S-adenosylmethionine (SAMe) by methionine adenosyltransferase (MAT1A/MAT2A). SAMe is the universal methyl donor for all cellular methyltransferase reactions: DNMT1 and DNMT3A/3B use it to methylate cytosine residues in CpG dinucleotides; EZH2 uses it for the H3K27me3 histone mark; COMT uses it to inactivate catecholamines; TPMT uses it to metabolize thiopurine drugs; PNMT uses it to convert norepinephrine to epinephrine; HNMT uses it to inactivate histamine; GNMT uses it in hepatic methyl group flux regulation; and phosphatidylethanolamine N-methyltransferase (PEMT) uses it for phosphatidylcholine synthesis in the liver. Every one of these processes is ultimately dependent on adequate B12 and folate.

When either B12 or folate is deficient, the functional consequence extends across all SAMe-dependent reactions simultaneously. The methylfolate trap is a key concept in understanding combined B12/folate deficiency: when B12 is absent, the methionine synthase reaction stalls, and folate becomes trapped as 5-MTHF without being able to regenerate THF. The cellular folate is still present but biochemically inaccessible, producing a functional folate deficiency even when dietary folate intake is adequate. This explains why B12 deficiency produces hematological findings identical to those of folate deficiency (megaloblastic anemia), and why treating B12 deficiency with high-dose folate temporarily corrects the blood picture while allowing neurological damage to continue. The neurological toxicity of B12 deficiency is independent of folate status and is mediated through the adenosylcobalamin-dependent mitochondrial pathway (methylmalonyl-CoA mutase deficiency) and through reduced SAMe-dependent myelin maintenance. Methylmalonic acid accumulates when adenosylcobalamin is absent, and elevated serum methylmalonic acid is the most sensitive and specific biomarker of functional B12 deficiency, detecting depletion weeks to months before serum B12 falls below normal reference ranges.

The clinical evidence for B12 and folate spans a remarkable breadth of conditions, reflecting the centrality of one-carbon metabolism to fundamental cellular processes. Neural tube defect prevention with periconceptional folate represents one of the highest-quality interventions in preventive medicine, with a number needed to treat below 1,000 in average-risk populations. Homocysteine-lowering trials (HOPE-2, VITATOPS, B-PROOF) have consistently demonstrated 25-30% plasma homocysteine reductions with B12/folate/B6 combinations but have produced mixed results on hard cardiovascular endpoints, with the most benefit in populations with high baseline homocysteine (>15 micromol/L) and deficiency states. The VITACOG trial demonstrated that B12/folate supplementation in older adults with elevated homocysteine reduced brain atrophy by 30% on MRI over 2 years, the first imaging evidence for neuroprotection from B vitamin supplementation. Colorectal cancer risk is consistently inversely associated with dietary folate intake in observational studies, though high-dose folic acid supplementation in colorectal adenoma trials has produced paradoxical results (possibly accelerating growth of established adenomas while preventing new ones), emphasizing the complexity of folate biology in cancer contexts. Overall, the strongest case for B12/folate supplementation is in individuals with documented deficiency, elevated homocysteine, MTHFR variants, pregnancy, strict veganism, long-term use of absorptioninhibiting medications (PPIs, metformin), and advanced age with gastric atrophy.

Mechanism of Action

One-Carbon Metabolism and SAMe Generation

Vitamin B12 and folate operate as an integrated system within one-carbon metabolism. The pathway begins with dietary folate, converted to dihydrofolate (DHF) and then to tetrahydrofolate (THF) by dihydrofolate reductase (DHFR). THF accepts one-carbon units from serine (via serine hydroxymethyltransferase, SHMT) to form 5,10-methyleneTHF, a branch point intermediate. From this branch point, the carbon unit can flow toward thymidylate synthesis (via thymidylate synthase, TS) for DNA replication, toward purine synthesis (via ATIC and PFAS), or toward homocysteine remethylation (via MTHFR reducing 5,10-methyleneTHF to 5-MTHF). The remethylation branch, requiring both 5-MTHF and methylcobalamin (vitamin B12), regenerates methionine from homocysteine via methionine synthase (MTR). Methionine is then adenosylated to SAMe by methionine adenosyltransferases, and SAMe donates its methyl group to over 200 methyltransferase reactions including DNMT1, DNMT3A, EZH2, COMT, TPMT, and PNMT.

Thymidylate and Purine Synthesis

The folate cofactor 5,10-methyleneTHF is the substrate for thymidylate synthase, the enzyme that produces dTMP from dUMP. dTMP is the precursor of dTTP, one of the four deoxyribonucleotide triphosphates required for DNA replication. In folate deficiency, dTMP production falls and dUTP accumulates, leading to uracil misincorporation into DNA at sites normally occupied by thymine. The base excision repair machinery attempts to correct uracil misincorporation but in the absence of adequate dTMP, the repair cycle is futile and creates strand breaks, ultimately causing the megaloblastic nuclear abnormalities characteristic of folate/B12 deficiency. Folate as 10-formylTHF is also required in two independent steps of de novo purine synthesis, linking folate status to the production of both adenine and guanine nucleotides needed for DNA and RNA synthesis.

Epigenetic Modulation

The link between B12/folate status and the epigenome is direct and biochemically fundamental: every DNA methylation event consumes SAMe, and the SAMe pool is continuously replenished by the folate-B12 cycle. DNMT1, the maintenance methylation enzyme, reads unmethylated CpG sites on newly synthesized daughter strands and installs the methyl group from SAMe to preserve the parental methylation pattern. DNMT3A and DNMT3B perform de novo methylation at previously unmethylated sites, guided by transcription factors and histone marks, also using SAMe. EZH2, the PRC2 methyltransferase, uses SAMe to install the H3K27me3 repressive histone mark at developmental gene promoters, a process required for differentiation and lineage commitment. When the SAMe pool is depleted by B12 or folate deficiency, all these methyltransferases are substrate-limited simultaneously. The consequence is a characteristic methylation drift: global CpG hypomethylation (as DNMT1 fails to maintain methylation at repetitive elements and low-CpG regions) combined with focal hypermethylation at specific promoters (paradoxically, as remaining SAMe is preferentially consumed at actively transcribed loci). This methylation instability is a mechanistic driver of the association between folate/B12 deficiency and increased cancer risk.

Mitochondrial Metabolism and Neuroprotection

The neuropathy of vitamin B12 deficiency involves a distinct mitochondrial pathway mediated by adenosylcobalamin. In the mitochondria, adenosylcobalamin is the cofactor for methylmalonyl-CoA mutase, the enzyme that converts methylmalonyl-CoA (derived from odd-chain fatty acid and amino acid catabolism) to succinyl-CoA for entry into the TCA cycle. When adenosylcobalamin is absent, methylmalonyl-CoA and methylmalonic acid (MMA) accumulate. MMA inhibits succinate dehydrogenase (Complex II of the electron transport chain) and impairs fatty acid beta-oxidation in neurons. Additionally, accumulated propionyl-CoA competes with acetyl-CoA in myelin lipid synthesis, incorporating abnormal odd-chain fatty acids into myelin and destabilizing its structure. Simultaneously, SAMe deficiency impairs the methylation of myelin basic protein and phosphatidylcholine (via PEMT), directly disrupting myelin synthesis and maintenance. These converging mechanisms explain the characteristic dorsal and lateral column demyelination and the irreversibility of established neurological damage if deficiency is prolonged.

Clinical Evidence

Neural Tube Defect Prevention

The MRC Vitamin Study (1991, n=1,817) established periconceptional folic acid as a definitive prevention for neural tube defect recurrence, with a 72% reduction at 4 mg per day. For primary prevention in average-risk women, the standard 400-800 mcg per day dose reduces first-occurrence risk by 60-70%. Mandatory grain fortification programs in the United States, Canada, and over 80 countries have reduced population-level neural tube defect rates by 25-50%, representing one of the largest measurable public health benefits of a nutritional intervention. For women with MTHFR C677T homozygosity, the recommended dose is higher (800 mcg-1 mg per day of 5-MTHF), and this population accounts for a disproportionate fraction of folate-responsive neural tube defects.

Megaloblastic Anemia

Both B12 and folate deficiency produce megaloblastic anemia through impaired thymidylate synthesis. Clinically, the two are distinguished by the neurological signs of B12 deficiency (absent in pure folate deficiency), serum methylmalonic acid (elevated only in B12 deficiency), and serum homocysteine (elevated in both). Treatment with the appropriate vitamin rapidly corrects the hematological findings (reticulocytosis within 5-7 days, normalization of MCV within 6-8 weeks), but neurological recovery from B12 deficiency is slower, incomplete after years of deficiency, and limited to the lesions that have not yet undergone axonal degeneration.

Cardiovascular Risk and Homocysteine Lowering

B12/folate supplementation consistently reduces plasma homocysteine by 25-30% in intervention trials. The HOPE-2 trial (n=5,522, mean follow-up 5 years) found that B12/folate/B6 supplementation reduced stroke risk by 25% (HR 0.75, p=0.02) despite no reduction in the primary composite endpoint (MI, stroke, cardiovascular death). The VITATOPS trial (n=8,164) found a non-significant trend toward reduced stroke and MI. These mixed results have been interpreted to indicate that homocysteine lowering is most beneficial in populations with high baseline homocysteine (>15 micromol/L) and insufficient in populations already on optimal cardiovascular medical therapy.

Cognitive Aging and Neurodegeneration

The VITACOG trial (Smith et al., 2010, n=168) remains the most compelling RCT evidence for B vitamin neuroprotection, demonstrating 30% slower brain atrophy by MRI over 2 years in older adults with mild cognitive impairment and elevated homocysteine who received B12/folate/B6. The benefit was significant only in those with baseline homocysteine above 13 micromol/L, implying that the protection is specific to deficiency-driven pathology rather than a general nootropic effect. A subsequent analysis (VITACOG, De Jager et al., 2012) found that the atrophy reduction was concentrated in the regions associated with Alzheimer pathology (hippocampus, cortical gray matter), strengthening the mechanistic connection.

Dosing Guidance

Standard supplemental dosing is 400-800 mcg per day methylfolate or folic acid (adults) and 500-1,000 mcg per day B12 for general nutritional support. For deficiency correction: oral B12 at 1,000-2,000 mcg per day is as effective as intramuscular injection for patients with dietary deficiency; pernicious anemia requires either high-dose oral (same range) or IM injection (1,000 mcg cyanocobalamin weekly for 4-8 weeks, then monthly). MTHFR C677T homozygotes should use 5-MTHF (methylfolate) 400-1,000 mcg per day and should have B12 checked concurrently. Measure serum methylmalonic acid (not just B12) to confirm true functional B12 status in older adults or those with suspected malabsorption.